A Prospective Evaluation of the Analytical Performance of GENECUBE HQ SARS-CoV-2 and GENECUBE FLU A/B.

Background: Molecular tests are the mainstay of detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, their accessibility can be limited by the long examination time and inability to evaluate multiple samples at once.

Objective: This study evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE HQ SARS-CoV-2 and GENECUBE FLU A/B.

Method: This prospective study was conducted between 14 December 2020 and 9 January 2021 at a polymerase chain reaction (PCR) center. Samples were collected from the nasopharynx with flocked swabs. Molecular tests were performed with the GENECUBE system and reference reverse transcription (RT)-PCR, and the results of the two assays were compared.

Result: Among 1065 samples, 81 (7.6%) were positive for SARS-CoV-2 on the reference RT-PCR. Three showed discordance between GENECUBE HQ SARS-CoV-2 and the reference RT-PCR; the total, positive, and negative samples of concordance for the two assays were 99.7%, 100%, and 99.7%, respectively. All discordant cases were positive with GENECUBE HQ SARS-CoV-2 and negative with the reference RT-PCR. SARS-CoV-2 was detected in all three samples using another molecular assay for SARS-CoV-2. For GENECUBE FLU A/B, the total, positive, and negative samples of concordance for the two assays were 99.5%, 100%, and 99.1%.

Conclusion: The GENECUBE HQ SARS-CoV-2 and GENECUBE FLU A/B demonstrated sufficient analytical performance to detect SARS-CoV-2 and influenza virus A/B.